Authors
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Sexual QOL improved at 12 months following AUS placement"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD.
Latest:
Malpractice Consult: What to know about closing arguments"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.”
Latest:
Financial toxicity is a growing concern in urologic oncology"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Latest:
Episode 2 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric ChallengesPanelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Latest:
Management of BCG-unresponsive NMIBC"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.
Latest:
Upper tract urothelial carcinoma: An in-depth review for urologists"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
Latest:
Tania Solomon, PA-C, highlights APP fellowship in urology“They come out of the fellowship competent and competitive in the field to any urology position that they're interested in,” says Tania Solomon, PA-C, MSc.
Latest:
Study shows HIFU noninferior to prostatectomy for localized prostate cancerTreating patients with localized prostate cancer with high-intensity focused ultrasound led to noninferior salvage treatment-free survival vs radical prostatectomy.
Latest:
Biomarker may predict MIBC status following neoadjuvant chemo"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.
Latest:
Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer CareThe conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.
Latest:
How to perform office-based blue light cystoscopyBLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Latest:
Trends in coding audits and what physicians can expectRecent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.
Latest:
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
Latest:
Transurethral resection of the bladder tumor: Standard technique and new advancementsImprovement in imaging modalities may help in performance of transurethral resection of the bladder tumor.
Latest:
The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
Expert shares key cybersecurity fundamentals and best practicesCybersecurity training is vital because it is mandated by HIPAA.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
Phase 3 CELLEBRATE trial testing regenerative stem cell-based therapy to improve urinary control for womenThe therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.
Latest:
Future Research and Development of Abiraterone Combination TherapiesIn this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.
Latest:
Expert urges widespread adoption of next-generation sequencing among physiciansNGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.
